Leveraging CRISPR/Cas9 To Overcome Hypoxic Barriers in Regenerative Dentistry.

Dental pulp stem cells (DPSCs) have gained increasing attention as a valuable cell source for regenerative dentistry owing to their accessibility, high proliferative potential, and capacity for multilineage differentiation. Despite these advantages, their therapeutic efficacy is substantially compromised by pathological hypoxia, a common feature of injured or poorly vascularized oral tissues. Hypoxic stress not only impairs DPSC survival but also diminishes their regenerative capacity, creating a major barrier to effective clinical translation. Addressing this limitation is therefore essential to harness the full therapeutic potential of DPSCs. Recent advances in genome-editing technologies, particularly the CRISPR/Cas9 system, have created novel opportunities to enhance the resilience of DPSCs against hypoxic stress. By enabling precise genetic modifications, CRISPR offers a powerful platform to reprogram cellular pathways associated with oxygen deprivation, oxidative stress, and apoptosis. Current preclinical investigations have focused on key targets such as HIF1α, PHD2, NRF2, BAX, and VEGF, exploring their modulation through CRISPR-mediated activation, inhibition, or knockout strategies. Upregulation of HIF1α and VEGF has demonstrated the ability to enhance angiogenesis and promote cell survival in oxygen-deficient microenvironments. Similarly, activation of NRF2 improves antioxidant defense mechanisms and mitigates oxidative damage, while suppression of pro-apoptotic genes such as BAX increases overall viability. Collectively, these strategies represent a multifaceted approach to strengthening DPSC performance in adverse conditions. The integration of CRISPR/Cas9 into regenerative dentistry represents a paradigm shift in addressing hypoxia-induced barriers to stem cell therapy. While early findings are promising, several critical challenges remain, including the potential for off-target effects, the need for stable and long-term genetic modifications, and concerns regarding biosafety and ethical considerations. Robust preclinical validation and carefully designed translational studies will be required before CRISPR-engineered DPSCs can be considered for clinical application. In summary, CRISPR/Cas9-based modulation of hypoxia-responsive pathways offers a transformative strategy to enhance the therapeutic efficacy of DPSCs. By improving survival, stress tolerance, and angiogenic potential under hypoxic conditions, this approach may significantly expand the clinical applicability of stem cell–based interventions in dentistry. Continued research is essential to ensure the safety, reliability, and long-term benefits of this promising therapeutic avenue.